Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Eli Lilly made the list due to the company's orforglipron diabetes drug, which analysts expect to show an Ozempic-like profile in its Q2 readout. "We see a high probability of success for the ...

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.